Revance Therapeutics
VerifiedDeveloping neuromodulators for the treatment of aesthetic and therapeutic conditions.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$482m (Public information from May 2024)
Share price
$2.84 RVNC
Nashville Tennessee (HQ)
Deals in current and previous year: